<DOC>
	<DOCNO>NCT00101010</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving rituximab together combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together combination chemotherapy work treat old patient diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Older Patients With Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical response rate old patient previously untreated aggressive diffuse large B-cell stage II-IV lymphoma treat rituximab , cyclophosphamide , pegylated doxorubicin hydrochloride liposome ( HCl ) , vincristine , prednisone . - Determine cardiotoxicity myelosuppression regimen patient . Secondary - Determine disease-free survival overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive rituximab intravenous ( IV ) , cyclophosphamide IV 1-1½ hour , pegylated doxorubicin HCl liposome IV 1 hour , vincristine IV day 1 , oral prednisone day 1-5 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 6 continue blood count recover OR pegfilgrastim SC day 6 ( 24 hour completion chemotherapy ) . Treatment repeat every 21 day 8 course absence unacceptable toxicity , disease progression , active hepatitis B virus infection , hepatitis . Patients response OR achieve less partial response 4 course remove study . Patients follow 1 month , every 3 month 1 year , every 4 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A maximum 80 patient accrue study within 27 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diffuse large Bcell lymphoma Stage II , III , IV disease Previously untreated disease Measurable evaluable disease No primary central nervous system ( CNS ) lymphoma follicular Bcell lymphoma PATIENT CHARACTERISTICS : Age 61 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3* Platelet count &gt; 100,000/mm^3* NOTE : * Unless due lymphomarelated hypersplenism bone marrow infiltration Hepatic Bilirubin &lt; 2 mg/dL Hepatitis B surface antigen negative Hepatitis B core antibody negative Hepatitis C Virus antibody negative Renal Creatinine &lt; 2 mg/dL Cardiovascular leave ventricular ejection fraction ( LVEF ) ≥ 50 % echocardiogram ple gate acquisition ( MUGA ) scan No uncontrolled hypertension cardiac symptom Cardiologist consultation require patient stage A cardiac failure follow know heart diseases : Diastolic dysfunction Prior coronary artery bypass graft Prior percutaneous transluminal coronary angioplasty Prior stent insertion Prior radiotherapy chest No myocardial infarction within past 6 month No New York Heart Association class IIIV heart failure No uncontrolled angina No severe uncontrolled ventricular arrhythmia No clinically significant pericardial disease No acute ischemic active conduction system abnormality electrocardiogram ( EKG ) Other Not pregnant nursing Fertile patient must use effective contraception No psychiatric illness would preclude study compliance give informed consent No major lifethreatening illness would preclude study treatment PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy See Cardiovascular Surgery See Cardiovascular</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>